Novartis (NVS.US) has submitted a new indication for its radioactive cancer therapy for market approval in China.
On April 28, the latest announcement on the CDE official website stated that Novartis (NVS.US) has had its application for a new indication for the lutetium [177Lu] tetrofosmin injection accepted.
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Earnings Week Ahead: MSFT, AAPL, META, AMZN, QCOM, PFE, MA, V, PYPL, ROKU, MCD, SBUX, KO, and More
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)
Catalyst Watch: Apple, Amazon & Microsoft's Earnings Confessions, Meta's LlamaCon and the Jobs Report
Report Says 25% Pharma Tariff Would Raise US Drug Prices by $51 Billion Annually, Reuters Reports
Expand
HH1000 : aren't they doing an offering. diluting shares. it's gonna make the price drop. no thanks for buying
Tonyco HH1000 :
DazzlerAus HH1000 : they are not necessarily doing an offering S3 expire it oretty standard for these conpanies to have a standing S3 in case its needed often it just insurance against an unexpected result ie if suddenly their main drug started resulting in bad side effects